Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

The high stakes for Huntington's patients

Summary by STAT
Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington’s disease, and the outcome could be potentially devastating for patients. That’s what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Holder joins the podcast for an in-depth discussion of how the regulator’s changing perspective on UniQure’s t…

1 Articles

STATSTAT
Center

The high stakes for Huntington's patients

Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington’s disease, and the outcome could be potentially devastating for patients. That’s what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Holder joins the podcast for an in-depth discussion of how the regulator’s changing perspective on UniQure’s t…

·Boston, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Thursday, January 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cambridge, Massachusetts icon

Cambridge, Massachusetts

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal